JNJ-64619178 (Synonyms: Onametostat) |
| Catalog No.GC19465 |
JNJ-64619178 (Onametostat) est un inhibiteur sélectif, actif par voie orale et pseudo-irréversible de la protéine arginine méthyltransférase 5 (PRMT5) avec une IC50 de 0,14 nM. JNJ-64619178 a une activité puissante dans le cancer du poumon.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2086772-26-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
JNJ-64619178 is a PRMT5 inhibitor with high selectivity and potency (PRMT5-MEP-50, IC50=0.14 nM), good pharmacokinetic properties and safety.
JNJ-64619178 can be combined with a SAM binding pocket to inhibit the function of PRMT/MEP50 in a time-dependent manner. Various cell lines exhibited different degrees of sensitivity to JNJ-64619178, indicating that JNJ-64619178 inhibits PRMT5 mainly by genomic rather than general targeted cytotoxicity [1].
The methylation of SMD1/3 protein can be selectively and effectively prevented by oral administration of 10 mg/kg JNJ-64619178 per day. SMD1/3 is a key component of the splice and a substrate for PRMT5/MEP50. In the biomarker-driven human small cell lung cancer xenograft model (NCI-H1048), JNJ-64619178 can cause tumor regression and prolong tumor growth inhibition after termination of administration [1].
Reference:
[1] Dirk Brehmer, et al. 108th Annu Meet Am Assoc Cancer Research
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *